Answers are grounded in this paper and cite their sources.
The first total synthesis of chiococcasaponin I (1), a 3,28-bidesmosidic oleanane-type triterpenoid saponin from Chiococca alba, is reported. The synthesis is convergent, assembling a triterpenoid aglycon fragment and a branched tetrasaccharide fragment prepared in parallel; the longest linear sequence proceeds in 13 steps from commercially available oleanolic acid. The central challenge—construction of the branched tetrasaccharide bearing two β-D-apiofuranoses and a rhamnose–arabinose core—was met by a chemoselective, sequential one-pot glycosylation that forges three glycosidic bonds in a single operation (47%): 3-O-glucuronidation of the aglycon, esterification at C-28 with the tetrasaccharide imidate, and global deprotection completed 1. In a C57BL/6J/OVA model, synthetic 1 displayed adjuvant activity, eliciting a Th1-skewed cellular response (elevated IFN-γ and IL-17, low IL-4) and a strong anamnestic anti-OVA antibody response after the booster dose that exceeded that of QS-21, with a milder injection-site reaction. This work provides synthetic access to a scarce natural adjuvant and broadens the repertoire of saponin-based vaccine adjuvants.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: